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Medical Microbiology and Infection Prevention, Gelre Hospitals, Apeldoorn, The NetherlandsAbstractThe prevalence of patients colonized with extended-spectrum beta-lactamase (ESBL)-producing bacteria increases, especially in long-term-
care facilities (LTCFs). Identiﬁcation of ESBL carriers at hospital admission is relevant for infection control measures and antibiotic
therapy for nosocomial infections. We aimed to develop a prediction rule for ESBL carriage at hospital admission for patients admitted
from home and LTCFs, and to quantify incidences of nosocomial infections caused by ESBL-producing bacteria. The ESBL-carrier status
was determined of patients admitted from LTCFs and from home settings in four hospitals in the Netherlands using perianal swabs
obtained within 48 hours of admission. Risk factors for ESBL carriage were assessed. Infections caused by ESBL-producing bacteria were
identiﬁed retrospectively.
Among 1351 patients, 111 (8.2%) were ESBL carriers at admission: 50/579 (8.6%) admitted from LTCFs and 61/772 (7.9%) from home
settings (p 0.63). Previous ESBL carriage and previous hospital admission were risk factors for ESBL carriage in multivariable analysis. The
area under the curve of the receiver operating characteristic curve of the model was 0.64 (95% CI 0.58–0.71). Presence of 1 risk
factor (n = 803; 59%) had sensitivity of 72%. Incidences of nosocomial infections caused by ESBL-producing bacteria were 45.5/10 000
and 2.1/10 000 admission days for ESBL carriers and non-carriers, respectively (p <0.05). In conclusion, prevalence of ESBL carriage at
hospital admission was 8.2%, and was comparable among patients admitted from LTCF and home. A clinically useful prediction rule for
ESBL carriage at admission could not be developed. The absolute incidence of nosocomial infections by ESBL-producing bacteria was low,
but higher among patients carrying ESBL-producing bacteria at the time of hospital admission.
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GA Utrecht, The Netherlands.IntroductionInfections due to extended-spectrum beta-lactamase (ESBL)-
producing bacteria are increasing worldwide [1,2], and areClinical Microbiology and Infection © 2014 European Society of Coften preceded by asymptomatic carriage, i.e. colonization [3].
Prevalence of ESBL carriage in hospitalized patients and patients
treated in long-term-care facilities (LTCFs) have been reported
to be as high as 27% [4,5], and the prevalence of ESBL-carriage
in non-hospitalized subjects seems to be increasing (www.isis-
web.nl) [6,7].
Identiﬁcation of ESBL carriers at hospital admission is rele-
vant for implementing appropriate infection control measures
and selecting empirical antibiotic therapy in case of nosocomial
infection (http://www.swab.nl/richtlijnen).Clin Microbiol Infect 2015; 21: 141–146
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2014.09.014
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care unit (ICU), intubation and mechanical ventilation, urinary
or arterial catheterisation, previous exposure to antibiotics, and
urinary tract infections have been identiﬁed as risk factors for
acquisition of ESBL-producing bacteria during hospital stay
[8–11]. In addition, LTCF residents are considered to have an
increased risk of ESBL carriage due to the presumed high risk
for acquisition and transmission of ESBL-producing bacteria in
these settings, facilitated by antibiotic use, understafﬁng, and
failing infection control measures [12]. However, risk factors
for ESBL carriage at the time of hospital admission have been
determined only prospectively in unselected hospitalized pa-
tients in 2006 [12].
We, therefore, prospectively determined the prevalence of
ESBL carriage in consecutively admitted patients coming from
LTCFs and home settings, and aimed to develop a prediction
rule for ESBL carriage at hospital admission. In addition, the
incidence of infections with ESBL-producing bacteria was
determined in patients identiﬁed as ESBL carriers at hospital
admission and non-carriers.MethodsSetting and patients
This study was conducted in four hospitals (one tertiary care
teaching hospital and three general teaching hospitals) in the
Netherlands between January 2010 and December 2012. All
patients admitted from LTCFs (nursing homes and rehabilita-
tion facilities) to one of the surgery or general medicine wards
were eligible for inclusion, as were patients admitted from
home during three periods of 9 weeks, at the beginning, middle,
and end of the study period in each hospital. Exclusion criteria
were age <18 years, an expected hospital stay <48 hours,
admission from another hospital, and inability to ﬁll out the
questionnaire and not having any relatives present to do so. The
institutional regulatory board approved the study and consid-
ered the culture scheme as part of “usual care.”
Study design
This was a prospective study. Perianal swabs, obtained within
48 hours of admission, were inoculated on an ESBL Brilliance
plate (Thermo Fisher Scientiﬁc, Loughborough, UK) to detect
ESBL-producing strains and on MacConkey agar (Thermo
Fisher Scientiﬁc) as a control for adequate sampling. In case of
no growth on both plates, patients were excluded from anal-
ysis. Isolates obtained from the ESBL Brilliance plates were
investigated by microarray analysis (Check-Points, Wageningen,
the Netherlands) for the presence of ESBL genes. DNA isola-
tion was performed using Ultraclean Microbial DNA IsolationClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectKit (Mo Bio Laboratories Inc., Carlsbad, CA, USA) according to
the instructions of the manufacturer.
Species identiﬁcation was performed using MALDI-TOF
(Bruker Daltonik, Bremen, Germany). Susceptibility was
determined by disk diffusion (ROSCO, Taastrup, Denmark) for
all antibiotics except for fosfomycin, which was tested by Etest
(BioMérieux, Marcy l’Etoile, France). Results were interpreted
using European Committee on Antimicrobial Susceptibility
Testing breakpoints.
A standardized questionnaire was used to collect informa-
tion on use of antibiotics or immunosuppressants, surgical
procedures, presence of indwelling devices, travel to foreign
countries, and work-related contact with animals in the year
before admission. Patients were encouraged to mark “un-
known” if they were uncertain whether they used antibiotics or
immunosuppressants. In case patients declared use or were
uncertain about use, this information was retrieved from their
pharmacy records. In addition, the pharmacy records of 50
patients who reported no use were randomly checked.
Departments were instructed to keep records of the num-
ber of patients that were not approached or refused
participation.
Microbiology databases were used to identify ESBL carriage
before admission, as well as presence of clinical cultures yielding
ESBL-producing bacteria during hospital stay. Hospital-acquired
infections (HAI) caused by ESBL-producing bacteria were
deﬁned as presence of a clinical culture with ESBL-producing
bacteria obtained more than 48 hours after hospital admission
that was treated by the clinician with antibiotics. Community-
acquired infections (CAI) caused by ESBL-producing bacteria
were deﬁned as presence of a clinical culture with ESBL-
producing bacteria obtained within 48 hours after hospital
admission that was treated by the clinician with antibiotics.
Statistical analysis
Statistical analyses were performed by χ2 test or Fisher’s exact
test for categorical data, and Student’s t test or Mann-Whitney
U test for continuous data. Backward multivariate logistic
regression analysis was conducted on variables signiﬁcantly
associated with carriage of ESBL-producing bacteria in univar-
iate analysis, after exclusion of multicollinearity, as well as some
other suspected important predictors. Variables with a p-value
<0.10 were included in the model. The model’s predictive
ability was examined using the area under the receiver oper-
ating characteristics curve. Calibration of the model was esti-
mated by the Hosmer-Lemeshow statistic in which a p-value
>0.20 indicates adequate ﬁt.
Missing data were replaced by multiple imputation (auto-
matic method) before univariate analysis. To obtain a weighted
score for the prediction rule, the regression coefﬁcients of theious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 141–146
TABLE 1. Possible risk factors in ESBL-positive and -negative patients, admitted from home and LTCFs, and missing values before
multiple imputation
Characteristics
Patients admitted from home Patients admitted from LTCFs
ESBL-negative
n (%)
n [ 711
ESBL-positive
n (%)
n [ 61
ESBL-negative
n (%)
n [ 529
ESBL-positive
n (%)
n [ 50
Sex Female 388 (55) 28 (46) 338 (64) 23 (46)
Male 323 (45) 33 (54) 191 (36) 27 (54)
Missing 0 (0) 0 (0) 0 (0) 0 (0)
Age, mean years (SD) 64 (18) 67 (15) 82 (12) 81 (12)
Previous AB (1 year) Yes 401 (56) 25 (41) 298 (56) 33 (66)
No 307 (43) 36 (59) 229 (43) 17 (34)
Missing 3 (0) 0 (0) 2 (0) 0 (0)
Previous IS (1 year) Yes 113 (16) 14 (23) 110 (21) 7 (14)
No 597 (84) 46 (75) 418 (79) 43 (86)
Missing 1 (0) 1 (2) 1 (0) 0 (0)
Previous admissions (1 year) Yes 268 (38) 33 (54) 208 (39) 26 (52)
No 442 (62) 28 (46) 317 (60) 23 (46)
Missing 1 (0) 0 (0) 4 (1) 1 (2)
Catheter Yes 63 (9) 7 (11) 90 (17) 16 (32)
No 647 (91) 54 (89) 435 (82) 34 (68)
Missing 1 (0) 0 (0) 4 (1) 0 (0)
Previous surgery (1 year) Yes 172 (24) 20 (33) 104 (20) 15 (30)
No 538 (76) 41 (67) 421 (80) 35 (70)
Missing 1 (0) 0 (0) 4 (1) 0 (0)
Previous travel (1 year) Yes 234 (33) 16 (26) 30 (6) 2 (4)
No 466 (66) 44 (72) 494 (93) 48 (96)
Missing 11 (2) 1 (2) 5 (1) 0 (0)
Occupation with animal contact Yes 13 (2) 1 (2) 1 (0) 1 (2)
No 642 (90) 55 (90) 528 (100) 49 (98)
Missing 56 (8) 5 (8) 0 (0) 0 (0)
Previous ESBL-carriage (1 year) Yes 5 (1) 7 (11) 6 (1) 4 (8)
No 706 (99) 54 (89) 523 (99) 46 (92)
Missing 0 (0) 0 (0) 0 (0) 0 (0)
AB, use of antibiotics; ESBL, extended-spectrum beta-lactamase; IS, use of immunosuppressants; LTCF, long-term-care facilities.
CMI Platteel et al. Beta-lactamase-producing bacteria 143predictive variables were rounded to the nearest number
ending in .5 or .0, resulting in a weighted score.
Isolates that grew on the ESBL Brilliance plate, but that were
not available for genotyping, were assumed ESBL positive. All
analyses were performed using SPSS 20 (IBM, Armonk, NY,
USA).ResultsIn total, 1531 patients were screened for ESBL carriage. Of
these, 180 patients were excluded from the study because their
cultures on both the MacConkey and the ESBL Brilliance agar
were negative. Therefore, a total of 1351 patients were
included: 579 (42.9%) admitted from >100 different LTCFs and
772 (57.1%) from the community. Patient characteristics are
depicted in Table 1. Populations admitted from home and
LTCFs at the four sites did not differ signiﬁcantly in gender or
previous ESBL carriage. In one hospital, the mean age for pa-
tients from home was higher (60 vs. 62 vs. 64 vs. 76 years; p
<0.01 for the last hospital, as compared to the other hospitals);
as for another hospital, the mean age for patients from LTCFs
was lower (74 vs. 81 vs. 82 vs. 86 years; p <0.01 for the ﬁrst
hospital, as compared to the other hospitals). In one hospital,
patients from home had fewer previous hospital admissions
(19% vs. 26% vs. 34% vs. 34%; p <0.01 for the ﬁrst hospital asClinical Microbiology and Infection © 2014 European Society of Clinical Microbiologycompared to the last two). Among populations admitted from
an LTCF, no statistically signiﬁcant differences were observed in
previous hospital admissions. For 71% of patients from LTCFs
and 55% of patients from home, information on use of antibi-
otics and immunosuppressants was retrieved from pharmacy
records. Among the 50 patients checked that declared no use,
only one had antibiotics in the year before admission and none
in the 6 months before admission.
The prevalence of ESBL carriage at hospital admission was
7.9% (n = 60; range per hospital 5.4–10.3%; n.s.) and 8.6%
(n = 51; range per hospital 5.3–18.8%; n.s.) for patients
admitted from home and LTCFs, respectively. There was no
signiﬁcant difference in ESBL prevalence among the four sites.
The prevalence of 18.8% (6/32) in one hospital among patients
from LTCFs resulted mostly from patients admitted from a
single LTCF with a known high endemic prevalence of ESBL
carriage. Four of the six patients in this hospital, being ESBL-
positive at admission, originated from this LTCF.
Species identiﬁcation and susceptibility testing was available
for 109 isolates from 97 patients. Susceptibility rates were for
tobramycin 77%, gentamicin 85%, ciproﬂoxacin 62%, trimeth-
oprim/sulfamethoxazole 35%, amikacin 100%, fosfomycin 84%,
and nitrofurantoin 77%.
Distribution of species and ESBL genes is shown in Table 2.
No differences were observed in distribution of genes between
patients admitted from home and LTCFs.and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 141–146
TABLE 2. Distribution of species and ESBL genesa
Species
Total
n [ 109
n (%)
CTX-M-1 group
n (%)
CTX-M-9
group
n (%)
SHV-4 group
n (%)
TEM-3 group
n (%)
SHV-2 group
n (%)
CTX-M-2
group
n (%)
SHV-4 group &
CTX-M-9 group
n (%)
Escherichia coli 74 (68) 48 (65) 11 (15) 8 (11) 6 (8) 1 (1)
Klebsiella pneumoniae 14 (13) 10 (71) 2 (14) 2 (14)
Enterobacter cloacae 13 (12) 3 (23) 7 (54) 1 (8) 2 (15)
Citrobacter freundii 3 (3) 2 (67) 1 (33)
Pseudomonas putida 2 (2) 2 (100)
Enterobacter asburiae 1 (1) 1 (100)
Kluyvera ascorbata 1 (1) 1 (100)
Morganella morganii 1 (1) 1 (100)
Total 109 (100) 66 (61) 22 (20) 8 (7) 7 (6) 3 (3) 1 (1) 2 (2)
ESBL, extended-spectrum beta-lactamase.
aIn two isolates, both CTX-M-9 and SHV-4 genes were detected.
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carriage were identiﬁed. These, together with age and patient
origin (LTCF or community), were included in multivariate
analysis after exclusion of multicollinearity, which yielded
documented ESBL carriage within 1 year before admission,
hospital admission in the previous 6 months, and male gender as
associated with ESBL carriage (Table 3). Twenty-two (2%) of
1351 patients had been identiﬁed as ESBL carriers in the 12
months before hospital admission, and 11 (50%) were still ESBL
carriers at hospital admission, yielding a sensitivity of 10% and
positive predictive value of 50% for prior ESBL carriage. The
area under the receiver operating characteristics curve of the
model based on these predictors was 0.64 (95% CI 0.58–0.71).
The goodness of ﬁt was adequate (Hosmer-Lemeshow statistic
p 0.60).
A strategy of screening patients with at least two statistically
signiﬁcant risk factors (15% of all patients) would identify 31%
of ESBL carriers, and screening all patients with at least one riskTABLE 3. Predictors of ESBL carriage at admission
Variable
Univariate
analysis
OR (95% CI)
Multivariate
analysis ﬁnal
model
OR (95% CI)
Patient admitted from LTCF 1.11 (0.75–1.66)a
Male 1.58 (1.06–2.36)b 1.49 (0.99–2.23)
Age (years) 0.99 (0.98–1.01)a
ESBL <1 year 12.99 (5.49–30.47)b 11.35 (7.22–17.84)
Penicillins <6 months 2.61 (1.54–4.44)b
Cephalosporins <6 months 1.78 (1.17–2.70)b
Fluoroquinolones <6 months 2.03 (1.26–3.28)b
Macrolides <6 months 1.54 (0.79–3.00)
Carbapenems <6 months 2.79 (0.69–11.25)
Tetracycline <6 months 1.82 (0.91–3.64)
Aminoglycosides <6 months 2.02 (0.40–10.27)
Sulfonamides/trimethoprim
<6 months
1.04 (0.49–2.22)
Immunosuppressants <6 months 1.27 (0.76–2.11)
Admissions <6 months 2.32 (1.55–3.47)b 2.13 (1.41–3.21)
External device 1.84 (1.12–3.03)b
Surgery 1.57 (1.02–2.41)b
Travel <1 year 0.69 (0.40–1.18)
Occupation with animal contact 1.41 (0.34–5.83)
ESBL, extended-spectrum beta-lactamase; LTCF, long-term-care facilities.
aVariables included in multivariable analysis based on evidence.
bVariables included in multivariable analysis based on OR.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectfactor (59% of all patients) would identify 72% of ESBL carriers
(Table 4). Thirty-one of the 111 patients carrying ESBL-
producing bacteria (28%) had none of the risk factors identi-
ﬁed in multivariate analysis.
Of these 31, 18 (58%) came from home and 13 from a LTCF.
The median age was 82 years (interquartile range 66–89 years).
Nine had travelled to foreign countries, but only four outside
Europe (one to Korea and New Zealand, one to Aruba and
Cuba, and two to Turkey). One worked with animals.
Of the 1351 patients included, 20 (1.5%) developed an
infection with ESBL-producing bacteria: 15 a CAI and ﬁve an
HAI. From the 111 patients identiﬁed as intestinal carriers at
admission, 13 (12%) developed a CAI and three an HAI (2%)
with ESBL-producing bacteria. From the 1240 patients not
identiﬁed as intestinal carriers, two developed a CAI (0.2%) and
two an HAI (0.2%) with ESBL-producing bacteria. The incidence
densities of hospital-acquired infection with ESBL-producing
bacteria were 45.5 (95% CI 9.4–132.8) and 2.1 (95% CI
0.26–7.7) per 10 000 admission days for patients carrying and
not carrying ESBL-producing bacteria at hospital admission.TABLE 4. Test characteristics of screening based on risk
factors
Risk factors Sensitivity Speciﬁcity PPV NPV
% Needed
to screen
Individual risk factors
Male gender 0.51 0.59 0.10 0.93 42
Previous admission 0.49 0.70 0.13 0.94 31
Previous ESBL carriage 0.10 0.99 0.50 0.92 2
Number of risk factors
1 0.72 0.42 0.10 0.94 59
2 0.31 0.87 0.17 0.93 15
3 0.054 1.00 0.75 0.92 1
Weighted scorea
1 0.72 0.42 0.10 0.94 59
2 0.51 0.70 0.13 0.94 32
3 0.33 0.86 0.17 0.94 16
6 0.10 0.99 0.50 0.92 2
7 0.09 1.00 0.67 0.92 1
8 0.07 1.00 0.67 0.92 1
9 0.05 1.00 0.75 0.92 1
ESBL, extended-spectrum beta-lactamase; NPV, negative predictive value; PPV,
positive predictive value.
aWeighted score: male gender 1 point, previous admission 2 points, previous ESBL
carriage 6 points.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 141–146
CMI Platteel et al. Beta-lactamase-producing bacteria 145One patient without positive screening cultures at admission
acquired ESBL-positive cultures during hospitalization but was
not treated.DiscussionIn this prospective, multicentre study of 1351 patients, the
prevalence of ESBL carriage at hospital admission was 8.2%, and
was comparable among patients admitted from LTCFs and home
settings. Despite the study size and detailed data collection, it was
not possible to develop a clinically useful prediction rule for ESBL
carriage at hospital admission. These ﬁndings underscore the
widespread occurrence of ESBL carriage and the difﬁculties for
developing targeted screening strategies to identify ESBL car-
riers. Incidence of nosocomial infections by ESBL-producing
bacteria was higher in ESBL carriers than in non-carriers.
The observed prevalence of ESBL carriage of 8.2% is
remarkably consistent with reported prevalences of 8.6% and
9.0% among healthy subjects in the Netherlands, with a mean
age of 33 and 43 years, respectively, screened before travel
departure to high-risk areas between 2010 and 2012.
Furthermore, the distribution of ESBL genes was comparable to
the reported distribution in clinical isolates from Dutch patients
in 2009 [13], suggesting that the molecular epidemiology of
ESBL-producing Enterobacteriaceae has remained unchanged
from 2009 to 2012.
In this study, prior ESBL carriage, hospital admission within
the last 6 months, and male gender were associated with ESBL
carriage, which conﬁrms results from previous studies
[9,14,15]. Although male gender has been identiﬁed as a risk
factor for ESBL carriage in previous studies as well, the biologic
substrate remains unknown [12]. We could not conﬁrm ﬁnd-
ings from two studies in Israel in which nursing home residence
was a risk factor for ESBL carriage at the time of hospital
admission [9,14]. Possibly, this is a result of the restrictive
antibiotic policy in the Netherlands. Although antibiotic use in
LTCFs is higher than in the community, this is still very low
compared to other countries [16,17]. Neither could we
conﬁrm use of antibiotics, diabetes mellitus, connective tissue
disease, and liver failure as risk factors [11]. Furthermore,
numbers of patients with an occupation involving animal con-
tacts or that had travelled to so-called high-risk countries were
too low in the current study to be identiﬁed as risk factor.
We could not develop a clinically useful prediction rule to
identify patients with ESBL carriage at the time of hospital
admission. The obtained area under the curve of the identiﬁed
risk factors for ESBL carriage at admission was 0.65 (95% CI
0.63–0.66). Increasing the positive predictive value toward
clinically useful values would reduce the sensitivity toClinical Microbiology and Infection © 2014 European Society of Clinical Microbiologyunacceptable low levels. Previous attempts in retrospective
studies in single centres or single wards, and with fewer patients
enrolled, also failed to develop such a prediction rule
[10,14,18]. This is possibly the result of heterogeneous trans-
mission routes that include nosocomial, household, and food
contacts. Antibiotic use and host susceptibility add further
complexity.
In the absence of a useful prediction rule, screening all
patients at admission could be considered. However, there is
currently no rapid detection tool available for ESBL carriage,
implying that in case of universal screening, patients should
either be pre-emptively isolated while awaiting culture results
or treated without precautions until results are available,
which is suboptimal for infection control. However, in an in-
ternational study in ICUs, universal screening and isolation of
detected carriers was not associated with a statistically sig-
niﬁcant reduction in ICU-acquired carriage with highly resis-
tant Enterobacteriaceae, as compared to isolation of detected
carriers alone [19]. Neither do the results of this study sup-
port universal screening. Although the risk of HAIs with an
ESBL-producing pathogen was signiﬁcantly higher in patients
with documented carriage of ESBL-producing bacteria at the
time of hospital admission, the absolute risk of infection was
low. In addition, three of the ﬁve patients with an HAI were
not colonized with ESBL-producing bacteria at the time of
hospital admission, and none of the observed infections could
be considered invasive. Furthermore, pre-emptive isolation is
probably not feasible in most settings. The association be-
tween ESBL carriage at admission and a higher risk to develop
an HAI with ESBL-producing bacteria, as compared to non-
carriers, was also observed in patients receiving liver trans-
plants in France [20]. Infections caused by ESBL-producing
bacteria occurred in 45% and 4% of patients identiﬁed as
ESBL carriers and non-carriers, respectively, before trans-
plantation. In contrast, such an association was not found in
neutropenic patients with hematologic malignancies, as the
total number of patients with documented infection was only
three [21].
Strengths of our study include the sample size of 1351 pa-
tients, the multicentre design, the inclusion of patients admitted
to different hospital wards, the enrichment of patients from
LTCFs, and the protocolized data collection.
Study limitations include the potential for inclusion bias, as
patients with inability to ﬁll out questionnaires were excluded
and severely ill patients were probably more likely to refuse
participation. Although departments were instructed to record
how many patients were not approached or refused partici-
pation, these data appeared to be unreliable. Possibly, inclusion
of comorbidities could have improved the prediction rule.
Although the ESBL microarray has been shown to match welland Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 141–146
146 Clinical Microbiology and Infection, Volume 21 Number 2, February 2015 CMIto the prevalent ESBL genes in the Netherlands, some ESBL-
producing strains might have been missed, as not all ESBL
types can be identiﬁed by the ESBL microarray [22]. Further-
more, the determination of HAIs caused by ESBL-producing
bacteria was a post hoc analysis, based on retrospective chart
review.
In conclusion, prevalence of ESBL carriage at admission was
8.2%, without elevated risk for patients from LTCFs. A clinically
useful prediction rule for ESBL carriage at admission could not
be developed. The incidence of nosocomial infections by ESBL-
producing bacteria was higher in ESBL carriers than in non-
carriers, but the absolute risk of an infection among ESBL
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